Crizotinib and ceritinib trigger immunogenic cell death via on-target effects - Sorbonne Université
Journal Articles OncoImmunology Year : 2021

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects

Abstract

Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib may act through off-target effects. However, we found that low-dose of ALK inhibitors, crizotinib and ceritinib, may stimulate ICD in anaplastic large cell lymphoma, in which ALK is activated due to a chromosomal translocation, suggesting on target ICD-promoting effects.
Fichier principal
Vignette du fichier
Crizotinib and ceritinib trigger immunogenic cell death via on target effects.pdf (948.07 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03417291 , version 1 (05-11-2021)

Identifiers

Cite

Adriana Petrazzuolo, Maria Perez-Lanzon, Peng Liu, M. Chiara Maiuri, Guido Kroemer. Crizotinib and ceritinib trigger immunogenic cell death via on-target effects. OncoImmunology, 2021, 10 (1), ⟨10.1080/2162402x.2021.1973197⟩. ⟨hal-03417291⟩
37 View
23 Download

Altmetric

Share

More